Frank Mottola, SVP and Chief Technology Operations Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.

Key Highlights

  • Reporting person: Frank Mottola, SVP, Chief Tech. Ops. Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
  • Transaction: Acquisition (Code A) of 100,000 restricted stock units (RSUs) on October 30, 2026
  • Price: RSUs were acquired at $0 per unit
  • Post-transaction holdings: 100,000 derivative securities beneficially owned directly following the reported transaction
  • Vesting trigger: 40% of RSUs vest upon the closing of the merger-of-equals between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.
  • Remaining vesting schedule: 15% vest at each of the one-, two-, three-, and four-year anniversaries of the merger closing
  • Settlement: RSUs are settled in common stock upon vesting

Mottola RSU Grant Details and Merger-Linked Vesting Schedule

According to the filing, Frank Mottola acquired 100,000 restricted stock units on October 30, 2026, under a direct ownership arrangement. The RSUs carry a conversion price of $0 and are linked to shares of Supernus Pharmaceuticals common stock on a one-for-one basis, with 100,000 underlying shares. The filing indicates this grant was made to Mottola in his capacity as SVP, Chief Technology Operations Officer of the company.

The filing's explanation of responses details a four-installment vesting structure. Specifically, 40% of the RSUs vest upon the closing of what the filing describes as "the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc." The remaining 60% is divided into four equal 15% portions vesting on the one-, two-, three-, and four-year anniversaries of that closing date. The RSUs are settled in common stock upon each vesting event.

The Form 4 was filed by Timothy C. Dec as attorney-in-fact for Mottola on November 2, 2026. No transactions were reported in Table I covering non-derivative securities. The filing does not indicate whether the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not selected.

What Was Disclosed

Supernus Pharmaceuticals (NASDAQ:SUPN) officer Frank Mottola disclosed the receipt of 100,000 RSUs on October 30, 2026, with vesting contingent primarily on the closing of a stated merger-of-equals transaction with Indivior Pharmaceuticals, Inc., followed by anniversary-based vesting installments.